Eugia Pharma Receives USFDA Approval for Prochlorperazine Edisylate Injection 10mg/2ml MDV
Published: July 14, 2022
Eugia US is pleased to announce that the company has received approval from the US Food & Drug Administration (USFDA) to manufacture and market Prochlorperazine Edisylate Injection 10mg/2ml MDV.
Indications for this product include:
- To control severe nausea and vomiting.
- For the treatment of schizophrenia.
Prochlorperazine has not been shown effective in the management of behavioral complications in patients with mental retardation.